GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » DA32 Life Science Tech Acquisition Corp (NAS:DALS) » Definitions » Intrinsic Value: Projected FCF

DA32 Life Science Tech Acquisition (DA32 Life Science Tech Acquisition) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 02, 2024)


View and export this data going back to 2021. Start your Free Trial

What is DA32 Life Science Tech Acquisition Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-02), DA32 Life Science Tech Acquisition's Intrinsic Value: Projected FCF is $0.00. The stock price of DA32 Life Science Tech Acquisition is $10.32. Therefore, DA32 Life Science Tech Acquisition's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for DA32 Life Science Tech Acquisition's Intrinsic Value: Projected FCF or its related term are showing as below:

DALS's Price-to-Projected-FCF is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.87
* Ranked among companies with meaningful Price-to-Projected-FCF only.

DA32 Life Science Tech Acquisition Intrinsic Value: Projected FCF Historical Data

The historical data trend for DA32 Life Science Tech Acquisition's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DA32 Life Science Tech Acquisition Intrinsic Value: Projected FCF Chart

DA32 Life Science Tech Acquisition Annual Data
Trend Dec21 Dec22
Intrinsic Value: Projected FCF
- -

DA32 Life Science Tech Acquisition Quarterly Data
Apr21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial - - - - -

Competitive Comparison of DA32 Life Science Tech Acquisition's Intrinsic Value: Projected FCF

For the Shell Companies subindustry, DA32 Life Science Tech Acquisition's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DA32 Life Science Tech Acquisition's Price-to-Projected-FCF Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, DA32 Life Science Tech Acquisition's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where DA32 Life Science Tech Acquisition's Price-to-Projected-FCF falls into.



DA32 Life Science Tech Acquisition Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



DA32 Life Science Tech Acquisition  (NAS:DALS) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

DA32 Life Science Tech Acquisition's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=10.32/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DA32 Life Science Tech Acquisition Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of DA32 Life Science Tech Acquisition's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


DA32 Life Science Tech Acquisition (DA32 Life Science Tech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
345 Park Avenue South, 12th Floor, New York, NY, USA, 10010
Website
DA32 Life Science Tech Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Executives
Da32 Sponsor Llc 10 percent owner 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Management Company, L.p. (series C) director, 10 percent owner, other: Director by deputization 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Arch Venture Fund Xi, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Section 32 Fund 3, Lp 10 percent owner, other: Director by Deputization 169 UNIVERSITY AVE., PALO ALTO CA 94301
Keith Crandell director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
William J Maris 10 percent owner, other: Director by Deputization 2033 SAN ELIJO AVE., #565, CARDIFF-BY-THE-SEA CA 92007
Angela Lai director 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Arch Venture Partners Xi, Llc 10 percent owner 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xi, L.p. 10 percent owner 8755 W HIGGINS RD., SUITE 1025, CHICAGO IL 60631
Section 32 Gp 3, Llc 10 percent owner, other: Director by Deputization 171 MAIN STREET, #671, LOS ALTOS CA 94022
Steven J. Kafka director, officer: Chief Executive Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Andrew Elbardissi director 2210 FARADAY AVE #100, CARLSBAD CA 92008
Chris Wolfe officer: Chief Financial Officer 230 PARK AVENUE SOUTH, 11TH FLOOR, C/O CAPITAL Z PARTNERS, NEW YORK NY 10003
Kristina Burow 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718